Unknown PHASE3 INTERVENTIONAL 2-arm NCT00131027

High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)

Randomized Controlled Trial to Test Efficacy of High-Dose Methotrexate Consolidation Therapy for BCR-ABL-Negative Acute Lymphoblastic Leukemia in Adults

Sponsor: Japan Adult Leukemia Study Group

Conditions Lymphoblastic Leukemia, Acute

Interventions Cyclophosphamide Cytarabine Daunorubicin Dexamethasone Doxorubicin Etoposide L-asparaginase Mercaptopurine Methotrexate Prednisolone Vincristine

Updated 5 times since 2017 Last updated: Nov 13, 2008 Started: Sep 30, 2002 Primary completion: Mar 31, 2011 Completion: Sep 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00131027, this PHASE3 trial focuses on Lymphoblastic Leukemia, Acute and remains ongoing. Sponsored by Japan Adult Leukemia Study Group, it has been updated 5 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Sep 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Japan Adult Leukemia Study Group

Data source: Japan Adult Leukemia Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nagoya, Japan